MedTrace Logo

Buccal Misoprostol and Intravenous Tranexamic Acid During Emergent Cesarean Delivery

NCT03777696 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-02-18

No results posted yet for this study

Summary

Purpose to evaluate the effects of buccal misoprostol with or without intravenous tranexamic acid (TA) in comparison with placebo on reducing post-partum hemorrhage in pregnant women undergoing emergent cesarean section

Conditions

  • Cesarean Section Complications

Interventions

DRUG

Misoprostol

400 μg of buccal misoprostol

DRUG

TA

1 gm of tranexamic acid in 100 ml saline iv

DRUG

placebo to misoprostol

placebo tablets to misoprostol buccal

DRUG

placebo to TA

110 ml saline iv

Sponsors & Collaborators

  • hany farouk

    lead OTHER

Principal Investigators

  • hany f sallam, md · Aswan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-31
Completion
2021-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777696 on ClinicalTrials.gov